The denominator swells in the high-risk arm
The peer-reviewed, multicentre, prospective observational study by Xu and colleagues enrolled 1,785 people from four countries and combined a ten-microRNA signature with carbohydrate antigen 19-9. In the testing cohort the signature had an area under the curve of 88.6 percent and 83.8 percent sensitivity for early-stage disease; the composite score reached 86.8 percent sensitivity for stage I–II disease.[1]
In the same cohort the false-positive rate was 3.2 percent in low-risk controls and 15.6 percent in high-risk controls. In 19 people the signature fell after chemotherapy and surgery and rose before recurrence; that is a direction signal, not an outcome proof.[1]
The limit of an observational design
The authors ask for larger prospective studies and list registry identifier NCT06388967. That does not generate bedside advice. The 64.3 percent potential for high-grade dysplasia in high-risk cysts is a separate, smaller question.[1]
The clinically useful sentence, as I read it, is that early-stage sensitivity only means something once it is said in which cohort the false-positive rate swells. Otherwise the headline is hope with the denominator hidden.[1]
Which cohort is the next signal?
The next useful report is whether a larger prospective study brings the high-risk false-positive rate below 15.6 percent. Until that figure moves, the assay remains a biomarker study.[1]